Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 801,727
  • Shares Outstanding, K 68,641
  • Annual Sales, $ 25,540 K
  • Annual Income, $ -192,500 K
  • 60-Month Beta 2.06
  • Price/Sales 29.18
  • Price/Cash Flow N/A
  • Price/Book 1.45
Trade EDIT with:

Options Overview Details

View History
  • Implied Volatility 106.34% ( +17.73%)
  • Historical Volatility 109.97%
  • IV Percentile 87%
  • IV Rank 61.31%
  • IV High 136.72% on 05/09/22
  • IV Low 58.20% on 11/22/21
  • Put/Call Vol Ratio 0.56
  • Today's Volume 781
  • Volume Avg (30-Day) 844
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 54,512
  • Open Int (30-Day) 62,178

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.84
  • Number of Estimates 8
  • High Estimate -0.72
  • Low Estimate -0.93
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -3.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.71 +20.29%
on 05/12/22
15.94 -26.73%
on 05/04/22
-1.88 (-13.86%)
since 04/27/22
3-Month
9.71 +20.29%
on 05/12/22
21.59 -45.91%
on 04/05/22
-5.22 (-30.89%)
since 02/25/22
52-Week
9.71 +20.29%
on 05/12/22
73.03 -84.01%
on 09/02/21
-22.91 (-66.23%)
since 05/27/21

Most Recent Stories

More News
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong...

EDIT : 11.68 (+7.55%)
Why Editas Medicine's Shares Fell 28.9% This Week

The company's progress for its lead therapy has been slow.

COMP : 6.01 (+12.13%)
EDIT : 11.68 (+7.55%)
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

EDIT : 11.68 (+7.55%)
AGLE : 1.5700 (+1.29%)
EYPT : 9.69 (+7.19%)
APLT : 1.5400 (+8.45%)
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Company on track to dose first transfusion-dependent beta thalassemia patient with EDIT-301 by year-end...

EDIT : 11.68 (+7.55%)
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels ...

EDIT : 11.68 (+7.55%)
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

VRTX : 273.73 (+1.51%)
VYGR : 6.05 (+5.22%)
EDIT : 11.68 (+7.55%)
ALGS : 1.2500 (+5.04%)
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 11.68 (+7.55%)
VBLT : 1.9500 (+10.17%)
Editas Medicine Announces First Quarter 2022 Results and Business Updates

Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman First pediatric patient dosed in Phase 1/2...

EDIT : 11.68 (+7.55%)
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four...

EDIT : 11.68 (+7.55%)
Interesting EDIT Put And Call Options For June 10th

Investors in Editas Medicine Inc saw new options become available this week, for the June 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain...

EDIT : 11.68 (+7.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Editas Medicine is a development-stage genome editing biotech, which makes medicines to treat serious diseases using its proprietary genome editing platform based on the unique Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. Though the company's discovery efforts target...

See More

Key Turning Points

3rd Resistance Point 13.12
2nd Resistance Point 12.43
1st Resistance Point 12.06
Last Price 11.68
1st Support Level 11.00
2nd Support Level 10.31
3rd Support Level 9.94

See More

52-Week High 73.03
Fibonacci 61.8% 48.84
Fibonacci 50% 41.37
Fibonacci 38.2% 33.90
Last Price 11.68
52-Week Low 9.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar